GET DAILY SIGNALSWhy Is QuidelOrtho (QDEL) Stock Down -6.01% Today?
Key Takeaways
- QuidelOrtho shares fell 6.01%, dropping $0.81 to $12.67 from a prior close of $13.48.
- The decline extends a volatile stretch driven by persistent China demand weakness, muted respiratory-testing demand, and a steep full-year guidance cut.
- Secondary pressure comes from balance-sheet concerns, including roughly $2.8 billion in net debt and negative cash generation.
- The move diverges from a steadier broader market, reflecting stock-specific fundamental and sentiment headwinds rather than a broad sector rotation.
- Traders are watching the company's third-quarter earnings report scheduled for November 3, 2026, as the next key catalyst.
- For deeper data on Price Targets, Earnings, and Forecast for QDEL, explore the dedicated analysis pages.
- Explore Trending AI Robots to see which AI trading strategies are currently outperforming in this environment.
Opening Summary
QuidelOrtho Corporation (QDEL), a global provider of in-vitro diagnostic solutions spanning clinical chemistry, immunoassay, immunohematology, and molecular testing, saw its shares fall sharply in Friday's session. The stock declined 6.01%, or $0.81, to trade at $12.67 versus a prior closing price of $13.48. The sell-off marks a continuation of recent volatility for the diagnostics maker, with markets attributing the move to lingering concerns around China-related purchasing disruptions, softer respiratory-testing demand, and the company's recently lowered financial outlook.
China Demand and Respiratory Headwinds Weigh on Sentiment
The primary overhang on QDEL remains weakness in its China business, where distributor purchasing has slowed following shifts in pricing guidance from the country's National Healthcare Security Administration. Management has signaled that these China-related challenges are expected to persist through the back half of the year. At the same time, respiratory-testing demand — a historically high-margin but variable revenue stream — has continued to underwhelm, with U.S. positivity rates and Southern Hemisphere flu-season data tracking below prior-year levels. Both factors directly pressure revenue and margins in the near term.
Full-Year Guidance Cut and Balance-Sheet Concerns
Investors are also contending with a meaningful downward revision to the company's full-year 2026 guidance. Management lowered its revenue outlook to a range of $2.52 billion to $2.60 billion and slashed adjusted EPS guidance to $0.65 to $0.90, while withdrawing free cash flow guidance altogether amid uncertainty in China and around respiratory-season strength. The company carries roughly $2.8 billion in net debt, largely from its 2022 acquisition of Ortho Clinical Diagnostics, which has amplified scrutiny of its cash generation and deleveraging path. These leverage and profitability concerns have kept a lid on the stock even as core laboratory and immunohematology franchises outside China remain relatively stable.
Market Context and Trading Activity
The decline in QDEL reflects stock-specific pressure rather than a broad healthcare-sector move, with the name trading independently of steadier major indices. The shares remain well below their 50-day and 200-day moving averages, and the session's move pushed the stock deeper below recently reclaimed levels near $14, underscoring weak technical positioning. Analyst sentiment has stayed cautious, with a consensus tilt toward "Reduce"/"Hold" ratings and a comparatively low average price target, reflecting diminished expectations for near-term earnings recovery.
What Comes Next for QDEL
The next decisive event for QDEL is its third-quarter 2026 earnings release, scheduled for after the market close on November 3, 2026. Investors will focus on China revenue trends, respiratory-season demand signals heading into the winter months, progress on the company's cost-optimization program, and any updates on cash flow and leverage reduction. Ongoing uncertainties include the durability of China headwinds, the trajectory of respiratory positivity rates, and the potential for strategic portfolio actions as the company works to strengthen its balance sheet. These factors leave the stock exposed to further volatility in the weeks ahead.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots from a broader platform that offers hundreds of automated strategies covering thousands of tickers. Only the strongest performers under current market conditions are featured, with bots differing by strategy, timeframe, performance metrics, and the symbols they trade. For traders seeking data-driven approaches to navigating volatile names, this section provides a useful starting point to explore.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
QDEL's RSI Oscillator peaks and leaves overbought zone
The 10-day RSI Oscillator for QDEL moved out of overbought territory on October 14, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 instances where the indicator moved out of the overbought zone. In 18 of the 19 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QDEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
QDEL broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for QDEL entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on QDEL as a result. In 56 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for QDEL just turned positive on September 28, 2026. Looking at past instances where QDEL's MACD turned positive, the stock continued to rise in 33 of 49 cases over the following month. The odds of a continued upward trend are 67%.
QDEL moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for QDEL crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +9.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where QDEL advanced for three days, in 177 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.521) is normal, around the industry mean (2.874). P/E Ratio (-0.874) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.274) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. QDEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QDEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of diagnostic healthcare solutions
Industry MedicalNursingServices
Advertisement